Squeezing Timelines and Development Costs – Solvias' Generic Methods for Biopharmaceutical Analysis
Costly delays owing to the unpredictable behavior of proteins are common during the development of analytical methods for the assessment and control of quality. The article describes how these risks may be minimized using a technology platform of generic methods designed for monoclonal antibodies or protein based biopharmaceuticals. A portfolio of 38 robust analytical methods cover the majority of needs. In problematic cases these may be extended by use of an automated LC/UPLC method development platform or a systematic evaluation of alternatives methods.